Hefei Lifeon Pharmaceutical Co., Ltd. (SHE:003020)
China · Delayed Price · Currency is CNY 22.85
-0.60 (-2.56%)
At close: May 12, 2026
SHE:003020 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,551 | 1,554 | 1,488 | 1,887 | 2,570 | 2,261 |
Other Revenue | - | - | 30.32 | 14.25 | 8.86 | 11.77 |
| 1,551 | 1,554 | 1,518 | 1,901 | 2,579 | 2,273 | |
Revenue Growth (YoY) | 0.36% | 2.33% | -20.11% | -26.31% | 13.46% | 20.01% |
Cost of Revenue | 539.94 | 550.81 | 479.46 | 932.11 | 1,619 | 1,369 |
Gross Profit | 1,011 | 1,003 | 1,039 | 968.68 | 960.28 | 904.36 |
Selling, General & Admin | 728.56 | 724.35 | 772.94 | 659.7 | 675.31 | 650.1 |
Research & Development | 110.08 | 110.78 | 91.78 | 84.96 | 73.8 | 65.86 |
Other Operating Expenses | 7.19 | 1.57 | 19.31 | 14.97 | 15.96 | 16.06 |
Operating Expenses | 844.48 | 836.69 | 887.09 | 762.82 | 765.5 | 731.99 |
Operating Income | 166.25 | 166.3 | 151.94 | 205.85 | 194.78 | 172.36 |
Interest Expense | -0.13 | - | -1.92 | -1.28 | -0.89 | -1.36 |
Interest & Investment Income | 24.21 | 27.72 | 13.62 | 32.14 | 36.68 | 14.58 |
Currency Exchange Gain (Loss) | - | - | 0.01 | 0.04 | 0.4 | -0.18 |
Other Non Operating Income (Expenses) | -2.29 | -1.79 | -0.75 | 0.92 | -0.17 | -0.34 |
EBT Excluding Unusual Items | 188.03 | 192.23 | 162.9 | 237.67 | 230.81 | 185.06 |
Gain (Loss) on Sale of Investments | -0.47 | 0.15 | 1.6 | 0.32 | -0.04 | -0.01 |
Gain (Loss) on Sale of Assets | -0 | -0 | 0.02 | - | -2.54 | -0.03 |
Asset Writedown | -8.63 | -10.58 | -6.43 | -0.12 | -0.39 | -0.27 |
Other Unusual Items | - | - | 13.72 | 19.55 | 11.98 | 10.09 |
Pretax Income | 178.94 | 181.8 | 171.82 | 257.42 | 239.82 | 194.84 |
Income Tax Expense | 19.4 | 18.24 | 19.34 | 23.53 | 30.57 | 22.61 |
Earnings From Continuing Operations | 159.53 | 163.55 | 152.48 | 233.88 | 209.25 | 172.23 |
Minority Interest in Earnings | 2.7 | 1.64 | 8.12 | -7.21 | - | - |
Net Income | 162.24 | 165.2 | 160.6 | 226.67 | 209.25 | 172.23 |
Net Income to Common | 162.24 | 165.2 | 160.6 | 226.67 | 209.25 | 172.23 |
Net Income Growth | -3.70% | 2.86% | -29.15% | 8.33% | 21.50% | 27.47% |
Shares Outstanding (Basic) | 189 | 190 | 191 | 192 | 189 | 188 |
Shares Outstanding (Diluted) | 189 | 190 | 191 | 192 | 189 | 188 |
Shares Change (YoY) | -1.59% | -0.68% | -0.47% | 1.75% | 0.49% | 33.01% |
EPS (Basic) | 0.86 | 0.87 | 0.84 | 1.18 | 1.11 | 0.92 |
EPS (Diluted) | 0.86 | 0.87 | 0.84 | 1.18 | 1.11 | 0.92 |
EPS Growth | -2.15% | 3.57% | -28.81% | 6.47% | 20.90% | -4.17% |
Free Cash Flow | 127 | 94.43 | 43.05 | 6.14 | -45.79 | -28.24 |
Free Cash Flow Per Share | 0.67 | 0.50 | 0.23 | 0.03 | -0.24 | -0.15 |
Dividend Per Share | - | - | 0.500 | 0.417 | 0.321 | 0.345 |
Dividend Growth | - | - | 19.99% | 30.02% | -7.16% | 40.04% |
Gross Margin | 65.18% | 64.55% | 68.42% | 50.96% | 37.23% | 39.78% |
Operating Margin | 10.72% | 10.70% | 10.01% | 10.83% | 7.55% | 7.58% |
Profit Margin | 10.46% | 10.63% | 10.58% | 11.92% | 8.11% | 7.58% |
Free Cash Flow Margin | 8.19% | 6.08% | 2.83% | 0.32% | -1.77% | -1.24% |
EBITDA | 253.31 | 250.93 | 226.84 | 241.56 | 220.72 | 199.92 |
EBITDA Margin | 16.34% | 16.15% | 14.94% | 12.71% | 8.56% | 8.79% |
D&A For EBITDA | 87.06 | 84.63 | 74.91 | 35.71 | 25.94 | 27.55 |
EBIT | 166.25 | 166.3 | 151.94 | 205.85 | 194.78 | 172.36 |
EBIT Margin | 10.72% | 10.70% | 10.01% | 10.83% | 7.55% | 7.58% |
Effective Tax Rate | 10.84% | 10.04% | 11.25% | 9.14% | 12.75% | 11.60% |
Revenue as Reported | - | - | 1,518 | 1,901 | 2,579 | 2,273 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.